SPRY
ARS Pharmaceuticals, Inc
NASDAQ: SPRY · HEALTHCARE · BIOTECHNOLOGY
$8.26
+5.36% today
Updated 2026-04-30
Market cap
$788.42M
P/E ratio
—
P/S ratio
9.36x
EPS (TTM)
$-1.74
Dividend yield
—
52W range
$7 – $19
Volume
1.5M
ARS Pharmaceuticals, Inc (SPRY) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-53.0%
Last 4 quarters
Revenue YoY growth
-67.6%
Most recent quarter
EPS YoY growth
-182.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-1.6%
2026-03-19
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-19 | $-0.42 | +1.1% | $8.30 | $8.17 | -1.6% |
| 2025-11-10 | $-0.52 | -13.0% | $8.85 | $8.77 | -0.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.42 | $-0.42 | +1.1% | $28.09M | -67.6% |
| 2025-09-30 | $-0.46 | $-0.52 | -13.0% | $32.50M | +1471.6% |
| 2025-06-30 | $-0.46 | $-0.46 | +0.0% | $15.72M | +3043.4% |
| 2025-03-31 | $-0.11 | $-0.35 | -218.2% | $7.97M | — |
| 2024-12-31 | $-0.12 | $0.51 | +534.0% | $86.58M | -288703.3% |
| 2024-09-30 | $-0.15 | $-0.20 | -33.3% | $2.07M | — |
| 2024-06-30 | $-0.12 | $-0.13 | -8.3% | $500000.00 | +4900.0% |
| 2024-03-31 | $-0.11 | $-0.11 | +0.0% | — | — |
| 2023-12-31 | $-0.14 | $-0.07 | +50.0% | $-30000.00 | — |
| 2023-09-30 | $-0.18 | $-0.16 | +11.1% | — | — |
| 2023-06-30 | $-0.17 | $-0.18 | -5.9% | $10000.00 | — |
| 2023-03-31 | $-0.17 | $-0.16 | +5.9% | $20000.00 | — |
Frequently asked questions
Has ARS Pharmaceuticals, Inc beaten earnings estimates?
ARS Pharmaceuticals, Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -53.0% over the last 4 quarters.
How does SPRY stock react to earnings?
SPRY stock has moved an average of -1.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is ARS Pharmaceuticals, Inc's revenue growth rate?
ARS Pharmaceuticals, Inc reported year-over-year revenue growth of -67.6% in its most recent quarter, with EPS growing -182.4% year-over-year.